Loyola University Medical Center

Gottlieb Memorial Hospital

MacNeal Hospital

Back to homepage
myLoyola

NCT00771173

CATHETER ANALGESIA TRIAL Phenazopyrdine vs. Placebo: a Randomized Controlled Trial

Official Title:

THE CAT(H) STUDY CATHETER ANALGESIA TRIAL Phenazopyrdine vs. Placebo: a Randomized Controlled Trial A CREST 2010 Project

Summary

The primary aim of this randomized clinical trial is to compare the utility of phenazopyridine HCl vs. placebo in reducing catheter-associated discomfort during the post-operative period in the gynecologic patient using mean VAS measurments.

Eligibility

Inclusion Criteria:

1. Adult women undergoing gynecologic surgery who are expected to tolerate oral medication within 12 post-operative hours and require an indwelling catheter for a minimum of 12 post operative hours after start of oral medication.

Exclusion Criteria:

1. Hypersensitivity to phenazopyridine products (Defined as a having a previous anaphylaxis reaction to phenazopyridine products).
2. Known contraindications to phenazopyridine HCl:

* Renal failure or insufficiency (Defined as having abnormal renal function on previous laboratory testing (BUN/Cr) or as having a known renal disease).
* History of hepatic disease or failure (Defined as having known liver disease or having elevated LFTs on previous laboratory testing. Patients who would not otherwise have such testing are not required to undergo special study labs).
* Known glucose-6-phosphate dehydrogenase deficiency.
3. Simultaneous suprapubic catheterization.
4. Inability to take oral medication within 12 hours after surgery.
5. Pregnant women.

Disease(s) and\or Condition(s)

Catheter-related Bladder Discomfort

Primary Purpose
  • TREATMENT
Intervention/Treatment
    • Type: DRUG
    • Name: phenazopyridine HCl
    • Description: Phenazopyrdine HCl 200 mg q8h x 24
    • Arm Group Labels: Study Medication Group
    • Type: OTHER
    • Name: Placebo
    • Description: Placebo tablet administered q8 hours for 24 hours postop.
    • Arm Group Labels: Placebo tablet Group
Sponsor
  • Loyola University